FacebookTwitterRedditEmail

Pharma Paid and Trump Delivered


How high are Pharma’s prices? Novartis wants $475,000 a patient for its new cancer therapy. Hep C drugs cost $95,000 for a course of treatment. The immune drug, Actimmune, costs $52,321.80 a month. The parasite drug Daraprim costs $45,000 a month. And the gallstone drug Chenodal costs $42,570 a month.

But this week in his long-awaited speech, Trump blamed foreign countries for high drug prices in the US and reversed his campaign pledge to use Medicare’s buying power to negotiate lower drug prices. Pharma stock prices rose; the shilling paid off.

Pharma has two lobbyists for every member of Congress. It spends more on lobbying than tobacco, oil and defense contractors combined. It parades patients before public and consumer panels to “provide media outlets a human face to attach to a cause when insurers balk at reimbursing patients for new prescription medications,” writes Melissa Healy of the Los Angeles Times.

And that is not enough for Pharma. Companies also try to incorporate in the UK, Ireland and other overseas locations to dodge the US taxes that fund them such as Medicare. They already manufacture and test drugs overseas because the labor is cheap.

The US government is captured. Pharma operatives head both Health and Human Services and the FDA. The CDC Foundation which receives millions from corporations (not that it affects policies or anything) lists as donors Abbott, AbbVie, Bayer, AstraZeneca, Merck, Pfizer, GlaxoSmithKline Biologicals, Eli Lilly, Amgen, Genentech, Gilead and many more. (Is that why the CDC allows its name to be used in Gilead ads for its Hep C drug?)

Until 2010, PhRMA, Pharma’s top lobbying group, was headed by former Louisiana Rep. Billy Tauzin who resigned from Congress where he chaired the committee which oversees the drug industryonly to immediately reappear as the leader of PhRMA where he drew a $2 million salary. No conflict of interest there.

Tauzin had played a key role in shepherding the Medicare Prescription Drug Bill through Congress which prohibited government negotiation of lower drug prices and Canadian imports. “It’s a sad commentary on politics in Washington that a member of Congress who pushed through a major piece of legislation benefiting the drug industry, gets the job leading that industry,” Public Citizen’s President Joan Claybrook said.

Two-thirds of Pharma lobbyists previously worked for Congress or federal agencies reports the New York Times. An aide to former Michigan Rep. John D. Dingell now works for PhRMA, and an aide to former Iowa Sen. Tom Harkin, who was the chairman of the Senate health committee “is now a top lobbyist for Merck.” Gary Andres, former staff director of the House Energy and Commerce Committee now lobbies for biotech companies. And the list goes on.

Having captured Congress, you wouldn’t think Pharma would need a charm offensive. Yet it spends millions trying to convince the public it has our interests at heart as it raises our taxes and health care costs. Currently, “America’s Biopharmaceutical companies” are running their “Go Boldly” campaign, ennobling their work with the pay-off line “here’s to permission to fail.”

Yes, Pharma knows a lot about “permission to fail.” Over 20 of its drugshave been withdrawn from the market in recent years because they were so dangerous—-after maximum money was made of course. They include Vioxx, Bextra, Baycol, Trovan, Meridia, Seldane, Hismanal, Darvon, Raxar, Redux Mylotarg, Lotronex, Propulsid, phenylpropanolamine (PPA), Prexige, phenacetin, Oraflex, Omniflox, Posicor, Serzone and Duract.

Pharma also runs a sappy “Hope to Cures: The Value of Biopharmaceutical Innovation and New Drug Discovery” campaign that showcases patients whose lives were saved by expensive drugs. “If you object to our six-digit drug prices you are signing the death warrant for these patients,” the sleazy campaign seeks to convey.

Two lies lurk under the PR stunt. First, most of Pharma’s profits come from non life-savingdrugs that treat acid reflux, ADHD, poor eating habits and a host of  trumped up psychiatric illnesses. Secondly, research accounts for only one-fifth of Pharma’s drug costs. Most drug costs Pharma seeks to recoup are for marketing––the ask-your-doctor ads you see on TV––and, of course, lobbying.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
April 02, 2020
Pam Martens - Russ Martens
The Dark Secrets in the Fed’s Last Wall Street Bailout Are Getting a Devious Makeover in Today’s Bailout
Jason Hirthler
The Temple of Self-Gratification
Eve Ottenberg
Prisons are a COVID-19 Petri Dish
P. Sainath
What We Should Do About COVID-19
Rev. William Alberts
The Coronavirus Rained on Trump’s Easter Charade
Stephen Corry
It’s Time to Clean Ecofascism Out of Environmentalism
Binoy Kampmark
The Swedish Alternative: Coronavirus as a Grand Gamble
Rebecca Gordon
The Future May Be Female, But the Pandemic is Patriarchal
Thomas Knapp
By The Time We Notice We’re Hungry, It May Be Too Late
David Rovics
An Open Letter to My Landlord #CancelRent
Simone Chun
Appeal for Humanitarian Diplomacy in the Korean Peninsula
Liu Jian
How COVID-19 Changed Our Lives: a Report From Beijing
Dean Baker
The Return of Infrastructure Week
Mike Garrity
Alliance for the Wild Rockies Sues Feds to Stop a Project That Will Kill 72 Yellowstone Grizzly Bears in Wyoming’s Upper Green and Gros Ventre Rivers
Elliot Sperber
Plague Days
April 01, 2020
Steve Early - Suzanne Gordon
No Pandemic-Related Pause? VA Privatization Leaves Veterans Waist Deep in Another Big Muddy 
Kenneth Surin
The UK and Covid-19 Crisis
Jack Wareham - Dylan Burgoon
“Whose University? Our University!” The Struggle for a COLA at UC Berkeley
Erik Molvar
Oil industry Exploits Pandemic as Excuse to Dodge Federal Regulations, Fees
Robert Jensen
Apocalypse, Now and Forever
Jake Johnston – Kira Paulemon
COVID-19 in Haiti: the Current Response and Challenges
Jen Moore
Guatemalan Water Protectors Persist, Despite Mining Company Threats
Danny Shaw
“The Coronavirus is Man-Made:” the Conspiracy Theory Trap 
Nafeez Ahmed
Former WHO Director: 8-Week Suppression Strategy Could Stop US COVID Crisis in Its Tracks
Frances Madeson
Death Camps in the Making: New York’s Prisons During a Time of Pandemic
Clark T. Scott
The White House and the CDC are United in Stupidity
George Ochenski
What Does COVID-19 Have to Do With Industrial Pollution?
Norman Solomon
Trump’s Mass Negligent Homicide Doesn’t Let Democratic Leaders Off the Hook
Scott Owen
Another New Peace
Elizabeth Schmidt
Lessons From Africa: Military Intervention Fails to Counter Terrorism
Greta Anderson
What’s the Hang Up on Releasing Adult Lobos?
Ted Rall
The Speech Trump Must But Cannot Give
Marshall Sahlins
Trumpty’s Country
March 31, 2020
Jonathan Cook
Netanyahu Uses Coronavirus to Lure Rival Gantz into ‘Emergency’ Government
Vijay Prashad, Du Xiaojun – Weiyan Zhu
Growing Xenophobia Against China in the Midst of CoronaShock
Patrick Cockburn
Trump’s Chernobyl Moment: the US May Lose Its Status as World Superpower and Not Recover
Roger Harris
Beyond Chutzpah: US Charges Venezuela With Nacro-Terrorism
M. K. Bhadrakumar
Has America Reached Its Endgame in Afghanistan?
Thomas Klikauer
COVID-19 in Germany: Explaining a Low Death Rate
Dave Lindorff
We’ve Met the Enemy and It’s a Tiny Virus
Binoy Kampmark
Barbaric Decisions: Coronavirus, Refusing Bail and Julian Assange
Nicolas J S Davies
Why is the U.S. so Exceptionally Vulnerable to Covid-19?
James Bovard
The Deep State’s Demolition of Democracy
Michael Doliner
Face Off: the Problem With Social Distancing
John Feffer
The Politics of COVID-19
FacebookTwitterRedditEmail